Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathew Lyons

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|December 22, 2020
Analysis of colectomy rates for ulcerative colitis in pre- and postbiological eras in Lothian, ScotlandPhilip W Jenkinson, Nikolas Plevris, Mathew Lyons, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 18, 2020
Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn's DiseaseNikolas Plevris, James Fulforth, Mathew Lyons, et al.
Therapeutic Advances in Gastroenterology|August 1, 2024
Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitisBeatriz Gros, Hannah Ross, Maureen Nwabueze, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 25, 2022
Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohn's diseaseLauranne A A P Derikx, Nikolas Plevris, Shanna Su, et al.
Digestive Diseases and Sciences|December 12, 2018
Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World OutcomesNikolas Plevris, Gareth R Jones, Philip W Jenkinson, et al.
Inflammatory Bowel Diseases|October 19, 2018
Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn's Disease Are Associated With Biologic RemissionNikolas Plevris, Mathew Lyons, Philip W Jenkinson, et al.
Gut|July 14, 2019
IBD prevalence in Lothian, Scotland, derived by capture-recapture methodologyGareth-Rhys Jones, Mathew Lyons, Nikolas Plevris, et al.
Alimentary Pharmacology & Therapeutics|March 18, 2022
Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysisMathew Lyons, Lauranne A A P Derikx, James Fulforth, et al.
NPJ Digital Medicine|November 19, 2021
Remote diagnosis of surgical-site infection using a mobile digital intervention: a randomised controlled trial in emergency surgery patientsKenneth A McLean, Katie E Mountain, Catherine A Shaw, et al.
Journal of Crohn'S & Colitis|June 5, 2021
Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational CohortsLauranne A A P Derikx, Heather W Dolby, Nikolas Plevris, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|December 22, 2020
Analysis of colectomy rates for ulcerative colitis in pre- and postbiological eras in Lothian, ScotlandPhilip W Jenkinson, Nikolas Plevris, Mathew Lyons, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 18, 2020
Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn's DiseaseNikolas Plevris, James Fulforth, Mathew Lyons, et al.
Therapeutic Advances in Gastroenterology|August 1, 2024
Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitisBeatriz Gros, Hannah Ross, Maureen Nwabueze, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 25, 2022
Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohn's diseaseLauranne A A P Derikx, Nikolas Plevris, Shanna Su, et al.
Digestive Diseases and Sciences|December 12, 2018
Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World OutcomesNikolas Plevris, Gareth R Jones, Philip W Jenkinson, et al.
Inflammatory Bowel Diseases|October 19, 2018
Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn's Disease Are Associated With Biologic RemissionNikolas Plevris, Mathew Lyons, Philip W Jenkinson, et al.
Gut|July 14, 2019
IBD prevalence in Lothian, Scotland, derived by capture-recapture methodologyGareth-Rhys Jones, Mathew Lyons, Nikolas Plevris, et al.
Alimentary Pharmacology & Therapeutics|March 18, 2022
Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysisMathew Lyons, Lauranne A A P Derikx, James Fulforth, et al.
NPJ Digital Medicine|November 19, 2021
Remote diagnosis of surgical-site infection using a mobile digital intervention: a randomised controlled trial in emergency surgery patientsKenneth A McLean, Katie E Mountain, Catherine A Shaw, et al.
Journal of Crohn'S & Colitis|June 5, 2021
Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational CohortsLauranne A A P Derikx, Heather W Dolby, Nikolas Plevris, et al.
Pageof 3